# Safety and Tolerability of RTX-134 in Adults With Phenylketonuria

> **NCT04110496** · PHASE1 · TERMINATED · sponsor: **Rubius Therapeutics** · enrollment: 1 (actual)

## Conditions studied

- Phenylketonurias

## Interventions

- **DRUG:** RTX-134

## Key facts

- **NCT ID:** NCT04110496
- **Lead sponsor:** Rubius Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-29
- **Primary completion:** 2022-12-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The trial was discontinued by the Sponsor
- **Last updated:** 2022-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04110496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04110496, "Safety and Tolerability of RTX-134 in Adults With Phenylketonuria". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04110496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*